Search research articles
Contact Us
Filters
Showing results (141-150 of 175) with videos related to
Page
of 18
Sort By:
The Annals of Pharmacotherapy
|
November 24, 1998
Neuropharmacology of St. John's Wort (Hypericum)
D A Bennett, L Phun, J F Polk, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1992
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic
R B Raffa, E Friderichs, W Reimann, et al.
Journal of Pharmacological and Toxicological Methods
|
March 21, 2001
Determination of the adsorption of tramadol hydrochloride by activated charcoal in vitro and in vivo
R B Raffa, C Wu, D J Stone, et al.
European Journal of Pain (London, England)
|
February 28, 2014
Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit
A Cowan, R B Raffa, C S Tallarida, et al.
Journal of Clinical Pharmacy and Therapeutics
|
April 20, 2011
A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia
K Akter, D A Gallo, S A Martin, et al.
Journal of Clinical Pharmacy and Therapeutics
|
June 26, 2002
Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
A F Maiorini, M J Gaunt, T M Jacobsen, et al.
Neuroscience
|
July 6, 2010
β-lactamase inhibitors display anti-seizure properties in an invertebrate assay
S M Rawls, F Karaca, I Madhani, et al.
Peptides
|
January 1, 1994
Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors
R B Raffa, A Kim, K C Rice, et al.
Journal of Clinical Pharmacy and Therapeutics
|
November 9, 2010
What do we (not) know about how paracetamol (acetaminophen) works?
K Toussaint, X C Yang, M A Zielinski, et al.
Journal of Clinical Pharmacy and Therapeutics
|
March 3, 2009
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
H Dhami, C E Fritz, B Gankin, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 175) with videos related to
Sort By:
Page
of 18
The Annals of Pharmacotherapy
|
November 24, 1998
Neuropharmacology of St. John's Wort (Hypericum)
D A Bennett, L Phun, J F Polk, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 1992
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic
R B Raffa, E Friderichs, W Reimann, et al.
Journal of Pharmacological and Toxicological Methods
|
March 21, 2001
Determination of the adsorption of tramadol hydrochloride by activated charcoal in vitro and in vivo
R B Raffa, C Wu, D J Stone, et al.
European Journal of Pain (London, England)
|
February 28, 2014
Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit
A Cowan, R B Raffa, C S Tallarida, et al.
Journal of Clinical Pharmacy and Therapeutics
|
April 20, 2011
A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia
K Akter, D A Gallo, S A Martin, et al.
Journal of Clinical Pharmacy and Therapeutics
|
June 26, 2002
Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
A F Maiorini, M J Gaunt, T M Jacobsen, et al.
Neuroscience
|
July 6, 2010
β-lactamase inhibitors display anti-seizure properties in an invertebrate assay
S M Rawls, F Karaca, I Madhani, et al.
Peptides
|
January 1, 1994
Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors
R B Raffa, A Kim, K C Rice, et al.
Journal of Clinical Pharmacy and Therapeutics
|
November 9, 2010
What do we (not) know about how paracetamol (acetaminophen) works?
K Toussaint, X C Yang, M A Zielinski, et al.
Journal of Clinical Pharmacy and Therapeutics
|
March 3, 2009
The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
H Dhami, C E Fritz, B Gankin, et al.
Page
of 18